Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity Citation: Coexistence of KRAS and BRAF mutations in colorectal cancer: a case report supporting the concept of tumoral het-erogeneity

Pegah Larki, Ehsan Gharib, Mohammad Yaghoob Taleghani, Fatemeh Khorshidi, Ehsan Nazemalhosseini-Mojarad, Hamid Aghdaei, Larki, Gharib, Yaghoob Taleghani, Khorshidi, Nazemalhosseini-Mojarad E, Asadzadeh Aghdaei
2017 CELL JOURNAL(Yakhteh)   unpublished
The detection of KRAS and BRAF mutations is a crucial step for the correct therapeutic approach and predicting the epidermal growth factor receptor (EGFR)-targeted therapy resistance of colorectal carcinomas. The concomitant KRAS and BRAF mutations occur rarely in the colorectal cancers (CRCs) with the prevalence of less than 0.001% of the cases. In patients with KRAS-mutant tumors, BRAF mutations should not regularly be tested unless the patient is participating in a clinical trial enriching
more » ... r the presence of KRAS or BRAF-mutated tumor. The current report demonstrates a case with advanced adenocarci-noma of the colon showing the coexistence of KRAS and BRAF mutations and may have profound clinical implications for disease progression and therapeutic responses.